Cargando…
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
PURPOSE: Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214559/ https://www.ncbi.nlm.nih.gov/pubmed/34163143 http://dx.doi.org/10.2147/PPA.S311674 |
_version_ | 1783710089520087040 |
---|---|
author | Chappuy, Mathieu Meroueh, Fadi Trojak, Benoit Bachellier, Jérôme Bendimerad, Patrick Kosim, Margaux Hjelmström, Peter Nubukpo, Philippe Brousse, Georges Rolland, Benjamin |
author_facet | Chappuy, Mathieu Meroueh, Fadi Trojak, Benoit Bachellier, Jérôme Bendimerad, Patrick Kosim, Margaux Hjelmström, Peter Nubukpo, Philippe Brousse, Georges Rolland, Benjamin |
author_sort | Chappuy, Mathieu |
collection | PubMed |
description | PURPOSE: Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations. PATIENTS AND METHODS: We carried out post-hoc analyses using data from the “AMBRE” survey, which was conducted among 366 individuals with OUD, that were recruited in 68 French addiction settings, including six prison medical centers. The reasons for interest in XR-BUP were compared between incarcerated and non-incarcerated interviewees, using logistic regressions models, which provided raw and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). Adjustment variables were gender, age category, level of education, and type of current medication for OUD, respectively. RESULTS: Data from 317 participants (ie, 221 non-incarcerated, and 96 incarcerated individuals) were included in the analyses. Adjusted comparisons found that “no longer taking a daily treatment” (aOR= 2.91; 95% CI= 1.21–6.98) and “having a more discreet medication” (aOR= 1.76; 95% CI= 1.01–3.10) were reasons that appealed more to incarcerated participants than to non-incarcerated ones. On the other hand, the potential reduction of withdrawal symptoms (aOR= 0.54; 95% CI= 0.29–0.99) or the risk of misuse (aOR= 0.56; 95% CI= 0.34–0.94) associated with XR-BUP treatment were considered more important by non-incarcerated individuals than by incarcerated ones. CONCLUSION: Incarcerated interviewees were interested in XR-BUP for different reasons than those outside prison. In particular, incarcerated patients were more interested in practicability and discretion features, and less in improving recovery or reducing misuse than non-incarcerated patients. |
format | Online Article Text |
id | pubmed-8214559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82145592021-06-22 Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder Chappuy, Mathieu Meroueh, Fadi Trojak, Benoit Bachellier, Jérôme Bendimerad, Patrick Kosim, Margaux Hjelmström, Peter Nubukpo, Philippe Brousse, Georges Rolland, Benjamin Patient Prefer Adherence Original Research PURPOSE: Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations. PATIENTS AND METHODS: We carried out post-hoc analyses using data from the “AMBRE” survey, which was conducted among 366 individuals with OUD, that were recruited in 68 French addiction settings, including six prison medical centers. The reasons for interest in XR-BUP were compared between incarcerated and non-incarcerated interviewees, using logistic regressions models, which provided raw and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). Adjustment variables were gender, age category, level of education, and type of current medication for OUD, respectively. RESULTS: Data from 317 participants (ie, 221 non-incarcerated, and 96 incarcerated individuals) were included in the analyses. Adjusted comparisons found that “no longer taking a daily treatment” (aOR= 2.91; 95% CI= 1.21–6.98) and “having a more discreet medication” (aOR= 1.76; 95% CI= 1.01–3.10) were reasons that appealed more to incarcerated participants than to non-incarcerated ones. On the other hand, the potential reduction of withdrawal symptoms (aOR= 0.54; 95% CI= 0.29–0.99) or the risk of misuse (aOR= 0.56; 95% CI= 0.34–0.94) associated with XR-BUP treatment were considered more important by non-incarcerated individuals than by incarcerated ones. CONCLUSION: Incarcerated interviewees were interested in XR-BUP for different reasons than those outside prison. In particular, incarcerated patients were more interested in practicability and discretion features, and less in improving recovery or reducing misuse than non-incarcerated patients. Dove 2021-06-14 /pmc/articles/PMC8214559/ /pubmed/34163143 http://dx.doi.org/10.2147/PPA.S311674 Text en © 2021 Chappuy et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Chappuy, Mathieu Meroueh, Fadi Trojak, Benoit Bachellier, Jérôme Bendimerad, Patrick Kosim, Margaux Hjelmström, Peter Nubukpo, Philippe Brousse, Georges Rolland, Benjamin Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder |
title | Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder |
title_full | Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder |
title_fullStr | Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder |
title_full_unstemmed | Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder |
title_short | Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder |
title_sort | factors of interest in extended-release buprenorphine: comparisons between incarcerated and non-incarcerated patients with opioid use disorder |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214559/ https://www.ncbi.nlm.nih.gov/pubmed/34163143 http://dx.doi.org/10.2147/PPA.S311674 |
work_keys_str_mv | AT chappuymathieu factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT merouehfadi factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT trojakbenoit factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT bachellierjerome factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT bendimeradpatrick factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT kosimmargaux factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT hjelmstrompeter factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT nubukpophilippe factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT broussegeorges factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder AT rollandbenjamin factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder |